Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Ajay K. Malik"'
Autor:
Ajay K Malik, Sophia Khaldoyanidi, Dominick L Auci, Scott C Miller, Clarence N Ahlem, Christopher L Reading, Theodore Page, James M Frincke
Publikováno v:
PLoS ONE, Vol 5, Iss 10, p e13566 (2010)
5-Androstene-3β,7β,17β-triol (β-AET), an active metabolite of dehydroepiandrosterone (DHEA), reversed glucocorticoid (GC)-induced suppression of IL-6, IL-8 and osteoprotegerin production by human osteoblast-like MG-63 cells and promoted osteoblas
Externí odkaz:
https://doaj.org/article/21de21ebb4a84ea1a5f7386efa808f38
Autor:
Ajay K. Malik, Stefanie Schanz, Farbod Shojaei, Hans-Peter Gerber, Napoleone Ferrara, Germaine Fuh, Megan Baldwin, Cuiling Zhong, Xiumin Wu
Publikováno v:
Nature Biotechnology. 25:911-920
Vascular endothelial growth factor (VEGF) is an essential regulator of normal and abnormal blood vessel growth. A monoclonal antibody (mAb) that targets VEGF suppresses tumor growth in murine cancer models and human patients. We investigated cellular
Autor:
Gloria Meng, Napoleone Ferrara, Wei-Ching Liang, Franklin Peale, Germaine Fuh, Ajay K. Malik, Henry B. Lowman, Hans-Peter Gerber, Megan Baldwin
Publikováno v:
Blood. 107:550-557
Vascular endothelial growth factor-A (VEGF-A) and its 2 transmembrane tyrosine-kinase receptors, VEGFR-1 and VEGFR-2, constitute a ligand-receptor signaling system that is crucial for developmental angiogenesis. VEGF-B and placental growth factor (Pl
Autor:
Ajay K. Malik, Hans-Peter Gerber
Publikováno v:
TARGETS. 2:48-57
Vascular endothelial growth factor (VEGF) is a crucial growth factor that mediates tumor angiogenesis, and thus many therapeutic agents are being developed to target VEGF or its receptors in the treatment of cancer. Early-phase clinical data indicate
Publikováno v:
The Journal of Gene Medicine. 5:11-17
Background Hemophilia B is an X-linked bleeding disorder that results from a deficiency in functional coagulation factor IX (hFIX). In patients lacking FIX, the intrinsic coagulation pathway is disrupted leading to a lifelong, debilitating and someti
Autor:
Gregg P. Solar, Ajay K. Malik, Daniel Eric Sherman, Xiao Huan Liang, James C. Marsters, Hans-Peter Gerber, Gloria Meng, Kyu Hong, Napoleone Ferrara
Publikováno v:
Nature. 417:954-958
Vascular endothelial growth factor (VEGF) is a principal regulator of blood vessel formation and haematopoiesis, but the mechanisms by which VEGF differentially regulates these processes have been elusive. Here we describe a regulatory loop by which
Publikováno v:
Archives of Virology. 146:601-609
The retroviral vectors based on an MFG-type backbone have superior expression characteristics, in part, due to the presence of the retroviral chimeric intron (MFG intron). We tested the hypothesis that inclusion of a second intron in MFG vectors may
Autor:
Ajay K. Malik, Sandra K. Weller
Publikováno v:
Journal of Virology. 70:7859-7866
UL9, the origin-binding protein of herpes simplex virus type 1, contains six sequence motifs conserved in a large superfamily of RNA and DNA helicases. Single-amino-acid substitution mutations in these motifs inactivate UL9 function in vivo (R. Marti
Publikováno v:
Pathobiology. 59:102-108
The AIMS/GRXII cell line is a product of the line of research our laboratory is pursuing to understand the response of target cells to sustained hormonal stimulation, a situation simulating the one that brings about in vivo tumorigenesis. The cell li
Autor:
Xiumin Wu, Franklin Peale, Wei-Ching Liang, Johnny Gutierrez, Hans-Peter Gerber, Y. Gloria Meng, Ajay K. Malik, Napoleone Ferrara, Germaine Fuh, Chingwei V. Lee, Ling Fu
Publikováno v:
The Journal of biological chemistry. 281(2)
To fully assess the role of VEGF-A in tumor angiogenesis, antibodies that can block all sources of vascular endothelial growth factor (VEGF) are desired. Selectively targeting tumor-derived VEGF overlooks the contribution of host stromal VEGF. Other